In 2025, Virbac achieved €1,465m in revenue, showing a 7.9% growth at constant exchange rates due to strong performance in the USA, IMEA, Latin America, and Europe. The company’s 2026 guidance includes expected revenue growth of 5.5-7.5% and adjusted recurring operating income around 17%, with strategic acquisitions like Thyronorm contributing positively.

For Q4 2025, Virbac reported €362m in revenue, representing a +7.1% growth at constant rates, driven by Europe, IMEA, and Pacific regions. The Farm Animal segment in Europe showed exceptional growth of +25%. North America saw growth of +5.5%, Latin America +2.7%, IMEA +12.6%, Far East Asia -1.6%, and Pacific +14.0%.

Overall in 2025, Virbac’s revenue reached €1,465m, with growth driven by Europe, North America, Latin America, IMEA, Far East Asia, and Pacific regions. The acquisition of Sasaeah and Mopsan contributed to growth. Europe grew by 7.5%, North America by 14.7%, Latin America by 7.5%, IMEA by 9.5%, Far East Asia by 3.3%, and Pacific by 0.1%.

Virbac’s recent acquisition of Thyronorm, a feline hyperthyroidism treatment, aligns with its growth strategy. The company expects the acquisition to positively impact sales and EBITDA margin from the first year. For 2026, Virbac anticipates revenue growth of 5.5-7.5% and an EBIT adjusted to revenue ratio of around 17%, factoring in the Thyronorm acquisition and US tariffs impact.

Virbac, a company dedicated to advancing animal health, reported strong growth in 2025 and strategic acquisitions like Thyronorm. The company’s commitment to innovation and investment in R&D position it well for continued success in 2026, with a focus on delivering comprehensive solutions to veterinarians, farmers, and pet owners worldwide.

Read more at GlobeNewswire: solid 2025 dynamic with annual revenue up +7.9% at